Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer.
10.3346/jkms.2016.31.8.1224
- Author:
Seung Eun LEE
1
;
So Young LEE
;
Hyung Kyu PARK
;
Seo Young OH
;
Hee Joung KIM
;
Kye Young LEE
;
Wan Seop KIM
Author Information
1. Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. wskim@kuh.ac.kr
- Publication Type:Original Article
- Keywords:
EGFR;
KRAS;
Pyrosequencing;
Cytology Specimen;
Mutation Test;
Lung Cancer
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Carcinoma, Non-Small-Cell Lung/genetics/metabolism/*pathology;
DNA Mutational Analysis;
DNA, Neoplasm/chemistry/metabolism;
Female;
Humans;
Lung Neoplasms/genetics/metabolism/*pathology;
Male;
Middle Aged;
Mutation;
Receptor, Epidermal Growth Factor/*genetics/metabolism;
Retrospective Studies;
ras Proteins/*genetics/metabolism
- From:Journal of Korean Medical Science
2016;31(8):1224-1230
- CountryRepublic of Korea
- Language:English
-
Abstract:
EGFR and KRAS mutations are two of the most common mutations that are present in lung cancer. Screening and detecting these mutations are of issue these days, and many different methods and tissue samples are currently used to effectively detect these two mutations. In this study, we aimed to evaluate the testing for EGFR and KRAS mutations by pyrosequencing method, and compared the yield of cytology versus histology specimens in a consecutive series of patients with lung cancer. We retrospectively reviewed EGFR and KRAS mutation results of 399 (patients with EGFR mutation test) and 323 patients (patients with KRAS mutation test) diagnosed with lung cancer in Konkuk University Medical Center from 2008 to 2014. Among them, 60 patients had received both EGFR and KRAS mutation studies. We compared the detection rate of EGFR and KRAS tests in cytology, biopsy, and resection specimens. EGFR and KRAS mutations were detected in 29.8% and 8.7% of total patients, and the positive mutation results of EGFR and KRAS were mutually exclusive. The detection rate of EGFR mutation in cytology was higher than non-cytology (biopsy or resection) materials (cytology: 48.5%, non-cytology: 26.1%), and the detection rate of KRAS mutation in cytology specimens was comparable to non-cytology specimens (cytology: 8.3%, non-cytology: 8.7%). We suggest that cytology specimens are good alternatives that can readily substitute tissue samples for testing both EGFR and KRAS mutations. Moreover, pyrosequencing method is highly sensitive in detecting EGFR and KRAS mutations in lung cancer patients.
